SERENTIL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an injectable small-molecule antipsychotic approved in 1970 for psychiatric indications. The drug is administered via injection and represents a legacy psychiatric therapeutic in Novartis's portfolio. Mechanism of action details are not publicly disclosed in available data.
LOE Approaching
Product is in decline phase with moderate competitive pressure (30/100); expect smaller team size and focus on defensive market preservation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERENTIL offers exposure to lifecycle management, market access strategy, and defensive commercial positioning in a mature therapeutic class. This role suits professionals focused on operational excellence and healthcare economics rather than product innovation.
Brand ManagerField Sales Representative
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.